De­nali claims a neu­ro­fil­a­ment vic­to­ry in Hunter syn­drome, two years af­ter let­ting down Wall Street

De­nali Ther­a­peu­tics once again tout­ed bio­mark­er da­ta for its ex­per­i­men­tal Hunter syn­drome drug Tues­day morn­ing, aim­ing to push the pro­gram to­ward FDA ap­proval af­ter …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER